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Abstract
Background: Optimal timing of noninvasive positive pressure ventilation (NIPPV) initiation in
patients with amyotrophic lateral sclerosis (ALS) is unknown, but NIPPV appears to benefit ALS
patients who are symptomatic from pulmonary insufficiency. This has prompted research proposals
of earlier NIPPV initiation in the ALS disease course in an attempt to further improve ALS patient
quality of life and perhaps survival. We therefore used a cost-utility analysis to determine a priori
what magnitude of health-related quality of life (HRQL) improvement early NIPPV initiation would
need to achieve to be cost-effective in a future clinical trial.
Methods: Using a Markov decision analytic model we calculated the benefit in health-state utility
that NIPPV initiated at ALS diagnosis must achieve to be cost-effective. The primary outcome was
the percent utility gained through NIPPV in relation to two common willingness-to-pay thresholds:
$50,000 and $100,000 per quality-adjusted life year (QALY).
Results: Our results indicate that if NIPPV begun at the time of diagnosis improves ALS patient
HRQL as little as 13.5%, it would be a cost-effective treatment. Tolerance of NIPPV (assuming a
20% improvement in HRQL) would only need to exceed 18% in our model for treatment to remain
cost-effective using a conservative willingness-to-pay threshold of $50,000 per QALY.
Conclusion: If early use of NIPPV in ALS patients is shown to improve HRQL in future studies, it
is likely to be a cost-effective treatment. Clinical trials of NIPPV begun at the time of ALS diagnosis
are therefore warranted from a cost-effectiveness standpoint.
Background
Respiratory failure is the most common cause of ALS
patient death[1]. Prior to respiratory failure, respiratory
muscle weakness can be measured by standard pulmo-
nary function tests including forced vital capacity
(FVC)[2]. Treatment of ALS patients with noninvasive
positive pressure ventilation (NIPPV) when FVC is less
than 50% appears to improve ALS patient survival[3,4]
and quality of life [5-7]. Improved survival of ALS patients
with NIPPV may be explained by a slower rate of pulmo-
nary function decline[4,5].
NIPPV initiated early in the ALS disease course may off-
load respiratory muscle work and thereby attenuate the
progressive decrease in pulmonary compliance seen in
ALS[8]. This treatment may also improve quality of life as
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ALS patients early in their course may experience non-spe-
cific symptoms of fatigue and lethargy, related to subtle
respiratory muscle weakness, which goes unrecognized or
is attributed to impaired mobility[2]. Whether initiation
of NIPPV at diagnosis, when FVC is typically reduced but
greater than 50%, slows the rate of pulmonary function
decline and improves quality of life and survival remains
to be studied in a clinical trial.
Paralleling proposed studies of feasibility and effective-
ness of early NIPPV[9] is a need to determine what mag-
nitude of health-related quality of life (HRQL)
improvement this proposed treatment needs to achieve to
be cost-effective. Quality of life improvement is an essen-
tial aspect of ALS treatment as curative treatments are not
available[10]. The possible improvement in HRQL from
early NIPPV treatment in ALS patients can be analyzed in
conjunction with the costs of early NIPPV with a cost-util-
ity analysis by using quality-adjusted life years (QALY) as
a measure of effectiveness. Cost-utility analyses tradition-
ally are used to determine which proven therapies are
cost-effective by determining a treatment's incremental
cost-effectiveness, that is, the cost per QALY gained rela-
tive to alternative treatments. In the "traditional" cost-util-
ity analysis, effectiveness has been proven, and an
estimate of benefit in health-state utility is already known.
As society's willingness-to-pay costs per QALY have been
reported,[11] the incremental cost-effectiveness can be
compared to this standard to determine whether a newly
proposed treatment is cost-effective. We applied this same
process to determine a priori, how much benefit early
NIPPV treatment in ALS patients would need to provide
for this treatment to be cost-effective. We reasoned that
should the degree of improvement determined in this
analysis seem plausible, future clinical trials testing early
NIPPV would be warranted from an economic perspec-
tive. If, on the other hand, the analysis showed that an
impractical degree of improvement would be necessary
for the treatment to be cost-effective, future clinical trials
of early NIPPV for ALS would be less worthwhile.
Methods
We calculated the benefit in health-state utility that early
NIPPV treatment of ALS patients must achieve to be cost-
effective. The primary outcome was the percent utility
gained through NIPPV in relation to two common will-
ingness-to-pay thresholds: $50,000 and $100,000 per
QALY[11].
Model
A decision tree modeled two alternative strategies: NIPPV
starting at the time of diagnosis versus no NIPPV at the
time of diagnosis, for a hypothetical cohort of patients
with a recent diagnosis of ALS. Eighty percent of ALS
patients have some evidence of respiratory muscle weak-
ness at the time of initial diagnosis[12]; while half of
patients demonstrate a reduction in FVC to less than 80%
(approximately two standard deviations below the nor-
mal range) at initial presentation[13]. It was assumed that
if early NIPPV is effective in preventing respiratory insuf-
ficiency, it should therefore be started at the time of
diagnosis.
Patients were allowed to shift through disease states
(mild, moderate, severe, terminal, or death) through
Markov processes. The probabilities of patients progress-
ing through these disease states over time were obtained
from the literature[14]. All patients were modeled to
begin in the mild stage, given their recent diagnosis. The
Markov models used the average amount of time patients
spend in each disease state, the probability of transition-
ing into a more severe stage of ALS, along with the utility
associated with the time spent in each health state, to esti-
mate the clinical and economic disease events over time.
Per practice guidelines recommending the initiation of
NIPPV based on an FVC < 50%, it was assumed that both
groups would be treated with NIPPV when these criteria
were met, and thus the analysis modeled only until this
point. The time horizon used was 1 year as this is the aver-
age time period between diagnosis and meeting the
NIPPV treatment criteria[3]. The reference case used a
benefit in health-state utility of 20% in the NIPPV group
compared with the non-NIPPV group. This is similar to
the improvement in patient QOL demonstrated for
NIPPV treatment in those who had respiratory muscle
weakness, hypoventilation, or sleep-disordered breath-
ing[7]. The improvement in health-state utility associated
with NIPPV use was allowed to vary in sensitivity analysis,
where one variable is allowed to vary over a plausible
range. One-way sensitivity analyses were conducted for
each variable across the ranges of values found in Table 1.
To account for patients entering the model at varying rates
of disease progression, the time horizon was adjusted. The
time horizon was varied between 6 months and 2 years, in
a one-way sensitivity analysis. As variations in FVC at
entry may relate to ALS disease stage at entry, we also con-
ducted a one-way sensitivity analysis on the probability of
entering the model in the mild stage, as opposed to the
moderate stage. Given that all patients are assumed to
have recently been diagnosed with ALS and have an FVC
> 50%, it was assumed that no one would enter the model
in a severe or terminal state. The decision tree was ana-
lyzed by Data 4.0 (TreeAge Inc, Williamstown, MA).
Utilities
Assessing health-state utilities in a patient population
allows assignment of a numerical value to patient reports
of HRQL or health state "utility" for different stages of dis-
ease. Health utilities were determined by assessment of
patient's health state at each level of disease by aBMC Health Services Research 2005, 5:58 http://www.biomedcentral.com/1472-6963/5/58
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preference-based method and have been reported previ-
ously in control arms of large clinical trials[15]. These
measurements were aggregated across individuals to
determine utility scores for each health state, ranging from
death (0), to perfect health (1). Utilities for each ALS
stage, measured by the EuroQol EQ-5D visual analogue
scale, were obtained from the literature[15].
Costs
Costs were estimated from the Medicare fee schedule for
2004 (in US dollars) for NIPPV and NIPPV accessories.
Medicare reimbursement was selected given the societal
perspective[16]. Costs of one month of NIPPV rental and
accessory costs were included for those intolerant to
NIPPV. No discounting of costs or utilities was needed
given the time horizon. Other costs related to ALS patient
care were considered equal in both treatment groups
given the identical probabilities of transitioning through
health states and were therefore not entered into the
model.
Results
The average patient receiving NIPPV experienced 0.59
QALYs at a cost of $1,773; a patient not receiving NIPPV
experienced 0.54 QALYs at a cost of $0, resulting in an
incremental cost-effectiveness ratio of $33,801. Sensitivity
analysis performed on the utilities of ALS states demon-
strated NIPPV has an incremental cost-effectiveness ratio
lower than $50,000 as long as the utility for ALS patients
receiving NIPPV is at least 13.5% higher at each stage than
those without NIPPV, meaning that early NIPPV is cost-
effective as long as the treatment of ALS patients with
NIPPV beginning at the time of diagnosis improves HRQL
by at least 13.5%. For a willingness-to-pay threshold of
$100,000 per QALY, the increase in HRQL with NIPPV
would only need to be 6.8% or greater to be cost-effective.
The cost-effectiveness did not exceed the $50,000 willing-
ness-to-pay threshold in any of the cost, transition proba-
bility, tolerance, or utility sensitivity analyses, meaning
that alterations of each variable across a plausible range
(Table 1) did not cause the incremental cost-effectiveness
of NIPPV to exceed $50,000 per QALY. Altering the toler-
ance of NIPPV below 18% would however cause the cost-
effectiveness to exceed $50,000 per QALY. No alteration
of the probability of entering the model in the mild dis-
ease stage caused the incremental cost-effectiveness of
NIPPV to exceed the $50,000 per QALY threshold. Shorter
time horizons were associated with a lower cost-effective-
ness ratio. A time horizon of 6 months was associated
with an incremental cost-effectiveness of $76,909, while
an 8 month time horizon was associated with incremental
cost-effectiveness of $53,001. Time horizons of 10
months or above were associated with an incremental
cost-effectiveness less than $50,000.
Discussion
The benefit of early NIPPV use in ALS patients has not yet
been studied. However, our cost-effectiveness model sug-
gests that NIPPV begun at the time of diagnosis would be
cost-effective if NIPPV were shown to improve HRQL by
just 7–14%.
The 7–14% range of HRQL improvement that would be
necessary in our model for early NIPPV to be cost-effective
may be an overestimate. The $50,000 per QALY threshold
for assessing cost-effectiveness is quite conservative. Given
more recent estimates of the appropriate cost-effectiveness
Table 1: Probabilities, utilities, and costs for base case and sensitivity analysis
Variables Reference case Lower value tested Upper value tested
Probabilities:
NIPPV tolerance 0.49[3] 0.40 0.80
Staying mild 0.66[14] 0.60 0.70
Staying moderate 0.77[14] 0.70 0.80
Staying severe 0.76[14] 0.70 0.80
Staying terminal 0.78[14] 0.70 0.80
Utilities:
Mild 0.8[15] 0.7 0.9
Moderate 0.6[15] 0.5 0.7
Severe 0.5[15] 0.4 0.6
Terminal 0.4[15] 0.3 0.5
Costs:
NIPPV and accessories for 1 
year
$3,132[17] $2,810 $3,306
A trial of NIPPV in those who 
prove intolerant
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threshold[11], the improvement that would be necessary
for NIPPV to be cost-effective is likely less than 7%. The
possibility that NIPPV could slow the transition from less
severe to more severe disease states was not taken into
account in the model. Should early NIPPV be demon-
strated to slow the progression of ALS[9], it would be even
more cost-effective than this model suggests.
Tolerability of NIPPV by ALS patients with early disease is
unknown. Tolerance of NIPPV (assuming a 20% improve-
ment in HRQL) would only need to exceed 18% in our
model for treatment to remain cost-effective using a con-
servative willingness-to-pay threshold of $50,000 per
QALY. This estimate of NIPPV compliance is well lower
than that seen in other studies[3]. The base case used a
much more conservative estimate of 49% tolerance[3].
The current analysis was limited by the validity of the esti-
mates used in the model. Tolerance of NIPPV adminis-
tered early in the course of ALS is unknown, but this value
was allowed to vary in sensitivity analysis. Utility values
were ascertained from estimates in the literature, but pre-
vious studies on this topic are limited. The utility values
were also allowed to vary in sensitivity analysis. In our
model, early NIPPV remained cost-effective in all of the
sensitivity analyses, supporting the robustness of the
model.
Conclusion
If early use of NIPPV in ALS patients is shown to improve
HRQL in future studies, it is likely to be a cost-effective
treatment. Further trials of early NIPPV initiation in ALS
patients are warranted, and supported from a cost-effec-
tiveness perspective.
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